Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118963 | 0.84 | MAPT (0.45) | ALDH1A1GAAGHSRMAPTKDM4E | |
| SCHEMBL4108251 | 0.81 | EPHX2 (0.52) | ALDH1A1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL4107606 | 0.80 | FPR3 (0.46) | ALDH1A1ACHEBACE1L3MBTL1CD274 | |
| SCHEMBL4123704 | 0.80 | DRD2 (0.53) | ACHEBACE1MAPTCD274DRD2 | |
| SCHEMBL4119993 | 0.79 | KDM4E (0.51) | ALDH1A1ACHEBACE1GAAL3MBTL1 | |
| SCHEMBL4114315 | 0.78 | EPHX2 (0.50) | ALDH1A1ACHEBACE1MAPTCD274 | |
| SCHEMBL4107368 | 0.75 | EPHX2 (0.47) | ALDH1A1ACHEGAAL3MBTL1MAPT | |
| SCHEMBL4115503 | 0.74 | KMT2A (0.54) | ALDH1A1GAAL3MBTL1MAPTKDM4E | |
| SCHEMBL4107385 | 0.72 | ALDH1A1 (0.53) | ALDH1A1ACHEBACE1GAAKDM4E | |
| SCHEMBL31619134 | 0.71 | MAPT (0.71) | ALDH1A1GAAGHSRMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | IL2, CASP2, MAVS | ALDH1A1 3256/4885ACHE 4505/4885BACE1 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.